SHANGHAI – Small-molecule oncology drug developer, Ascentage Pharma Group, of Taizhou, Zhejiang, has raised ¥500 million (US$72 million) from Future Industry Investment Fund, a private equity fund managed by China's State Development & Investment Corporation Fund Management Corp. Ltd. (SDIC).